张氏挑割疗法联合盐酸西替利嗪治疗慢性自发性荨麻疹的随机对照试验
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:

上海市黄浦区卫生健康委员会资助项目(HZM202101).


Zhang’s cutting therapy combined with cetirizine hydrochloride for chronic spontaneous urticaria: a randomized controlled trial
Author:
Affiliation:

Fund Project:

undefined

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的 观察张氏挑割疗法联合盐酸西替利嗪治疗慢性自发性荨麻疹的临床疗效及对炎症反应和免疫功能的影响。方法 将符合纳入标准的64例慢性自发性荨麻疹患者随机分为两组,每组32例。试验组接受张氏挑割疗法联合盐酸西替利嗪治疗,对照组接受盐酸西替利嗪单药治疗。治疗4周后,依据《中国荨麻疹诊疗指南(2018版)》评估两组患者的临床疗效并计算总有效率[(显效患者的例数+有效患者的例数)/总患者例数×100%],通过荨麻疹控制评分量表(UCT)和荨麻疹活动度评分量表分别评估疾病控制情况和活动度,并比较两组患者血清学指标(总IgE、CRP、嗜酸性粒细胞比例、补体C3、补体C4)及外周血T淋巴细胞亚群(CD4+、CD8+和CD4+/CD8+)水平。随访6个月,统计两组显效和有效患者的复发情况。结果 共60例患者纳入最终结果统计,试验组治疗总有效率为93.33%(28/30),对照组治疗总有效率为66.67%(20/30),试验组治疗总有效率高于对照组(P=0.023)。治疗后,两组UCT评分均高于治疗前、UAS评分均低于治疗前(均P<0.001),且试验组治疗后UCT评分高于对照组、UAS评分低于对照组(P<0.001)。治疗后,试验组CRP水平较治疗前下降、对照组CRP水平较治疗前升高(均P<0.05),且试验组治疗后CRP水平低于对照组(P<0.001);治疗后两组血清总IgE水平、嗜酸性粒细胞比例、补体C3、补体C4、CD4+、CD4+/CD8+水平较治疗前均无明显变化,且组间比较差异无统计学意义(均P>0.05)。随访6个月,试验组复发率(3.57%,1/28)低于对照组(45.00%,9/20),差异有统计学意义(P<0.05)。结论 针对慢性自发性荨麻疹患者,张氏挑割疗法联合盐酸西替利嗪临床疗效优于单用盐酸西替利嗪,能够降低CRP水平,且复发率低。

    Abstract:

    Objective To observe the clinical efficacy of Zhang’s cutting therapy combined with cetirizine hydrochloride in treating chronic spontaneous urticaria (CSU) and its impacts on inflammatory response and immune function. Methods Sixty-four patients with CSU who met the inclusion criteria were randomly assigned to 2 groups, with 32 cases in each group. The trial group received Zhang’s cutting therapy combined with cetirizine hydrochloride, while the control group received cetirizine hydrochloride monotherapy. After 4 weeks of treatment, the clinical efficacy was assessed according to the Chinese guidelines for the diagnosis and treatment of urticaria (2018 edition), and the overall response rate was calculated ([number of markedly improved patients+number of effective patients]/total number of patients×100%). Disease control and activity were evaluated using the urticaria control test (UCT) and urticaria activity score (UAS), respectively. Serum levels of total immunoglobulin (Ig)E, C reactive protein (CRP), eosinophil percentage, complements 3 and 4 (C3 and C4), and peripheral blood T lymphocyte subsets (CD4+, CD8+ and CD4+/CD8+) were compared between the 2 groups. Patients were followed up for 6 months to document recurrence among those with marked improvement or effective response. Results A total of 60 patients were included in the final analysis. The overall response rate was 93.33% (28/30) in the trial group and 66.67% (20/30) in the control group, with the trial group showing a significantly higher response rate than the control group (P=0.023). After treatment, UCT scores increased and UAS scores decreased in both groups compared with baseline (both P<0.001), with the trial group showing higher UCT scores and lower UAS scores than the control group post-treatment (both P<0.001). CRP levels decreased in the trial group but increased in the control group compared with baseline (both P<0.05), and post-treatment CRP levels were lower in the trial group than in the control group (P<0.001). No significant changes were observed in serum total IgE levels, eosinophil percentage, C3, C4, CD4+, and CD4+/CD8+ in either group after treatment, with no significant between-group differences (all P>0.05). During the 6-month follow-up, the recurrence rate was significantly lower in the trial group than in the control group (3.57% [1/28] vs 45.00% [9/20], P<0.05). Conclusion For patients with CSU, Zhang’s cutting therapy combined with cetirizine hydrochloride demonstrates superior clinical efficacy to cetirizine hydrochloride monotherapy by reducing CRP levels and achieving a lower recurrence rate.

    参考文献
    相似文献
    引证文献
相关视频

分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2025-06-19
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2026-03-25
  • 出版日期: 2026-03-20
文章二维码
重要通知
友情提醒: 近日发现论文正式见刊或网络首发后,有人冒充我刊编辑部名义给作者发邮件,要求添加微信,此系诈骗行为!可致电编辑部核实:021-81870792。
            《海军军医大学学报》编辑部
关闭